It is now obvious that adipose tissue synthesises and secretes many biologically active products that exert effects either within the adipose tissue itself or its surrounding tissues Ð ie these secreted agents have autocrine or paracrine actions. However, adipose tissue also secretes compounds into the blood to affect other target tissues, and can now be considered to be an endocrine organ. The presentations in this session of the symposium described examples of both types of secretion, with angiotensin and nitric oxide (NO) representing autocrineaparacrine adipose tissue secretions, and leptin and tumour necrosis factor-a (TNFa) being examples of endocrine (and probably autocrine) secretions.
The ®rst presentation by Go Èkhan Hotamisligil concerned the role of adipose tissue in the development of insulin resistance, and concentrated mainly on the role of the cytokine TNFa. Apart from insulin resistance, Hotamisligil showed how increased secretion of TNFa could also explain many other adverse metabolic consequences of obesity, such as impaired thermoregulation and cardiovascular disorders resulting from changes in platelet activity and plasma triglyceride levels. In some remarkable studies using genetic ablation of function involving a targeted null mutation of the TNF gene, there was a signi®cant improvement in insulin receptor signalling and sensitivity in two animal models of obesity involving diet and chemical (gold thioglucose) induced obesity. Improvements in glucose homeostasis could also be demonstrated in genetically obese (obaob) mice in which TNF receptor signalling had been disrupted due to targeted mutations in the receptor genes. Clearly, this adipose tissue-derived cytokine seems to play a very important, albeit not exclusive, role in developing some of the comorbidities associated with obesity. If the same holds true for humans, this could offer the potential for developing agents to suppress or antagonize the actions of TNFa in the treatment of some of the comorbidities, if not of obesity itself.
Leptin, like TNFa, can be considered to be a cytokine, particularly as the structure of the leptin receptor conforms to that of other cytokine receptors. However, leptin is better known as a hormone secreted by adipose tissue that acts via the hypothalamus to regulate the size of the body's fat stores. One of the major problems with this concept of leptin as a lipostatic hormone is that it fails to prevent the accumulation of adipose tissue in most examples of diet-induced obesity Ð both animal and human. While there is no doubt that an absence or low levels of leptin activates compensatory mechanisms (hyperphagia and depressed thermogenesis) that result in the repletion of fat stores and restoration of leptin levels to normal, the fact that the hyperleptinaemia seen in obesity fails to inhibit food intake andaor activate thermogenesis has been ascribed to leptin resistance. However, there may be some other role for leptin in situations when levels are high and fat stores are replete.
Given the possibility of some other, additional role for leptin, one can see the attraction of Roger Unger's hypothesis that leptin acts to prevent lipid deposition in other tissues (tissues other than adipose tissue), thereby avoiding the lipotoxic effects of excessive triglyceride deposition in organs such as the heart, skeletal muscle and, particularly, pancreatic islets. In the second presentation of this session, Unger describes how lipapoptosis could result from excess triglyceride accumulation and formation of cytotoxic levels of ceramide. On the basis of Unger's hypothesis, one may have to reconsider the de®nition of leptin resistance. For example, increasing circulating levels of leptin associated with increasing adiposity should not be construed as leptin resistance, provided the hormone was seen to be acting to con®ne the storage of triglyceride to adipocytes while limiting storage in non-adipocytes. In other words, one would require evidence of excessive lipid accumulation and lipotoxicity in non-adipose tissues before one could invoke leptin resistance.
Endocrinologists are all too familiar with the role of the kidney and the renin ± angiotensinogen ± aldosterone system in the control of sodium balance and bodȳ uid volume regulation, and it is unlikely that they would have felt it necessary to implicate adipose tissue in this homeostatic system. However, Ge Ârard Ailhaud described some remarkable studies showing that adipose tissue has its own, local renin ± angiotensinogen system (RAS). The adipose tissue RAS appears to provide an autocrineaparacrine mechanism in¯uencing adipose tissue differentiation and development, but Ailhaud's presentation also raised the tantalizing prospect that adipose tissue could participate, together with the renal ± plasma RAS system, in the control of blood pressure. Such a link might help to explain why hypertension is often associated with obesity. This, however, is speculation, and should not detract from Ailhaud's main thesis that the adipose tissue RAS system acts as an autocrineaparacrine mechanism in adipose tissue development.
Another autocrineaparacrine mechanism identi®ed in adipose tissue involves nitric oxide (NO). Andre Â Marette produced evidence to show that adipose tissue expresses the inducible NO synthase isoform (iNOS) and that administration of endotoxin increases the expression of iNOS in both white and brown adipose tissue. It is still much too early to say what the normal, physiological function of NO in adipose tissue is, but Marette has shown that it may have an important role in endotoxaemia, possibly via modulation of glucose transport and lipoprotein hydrolysis.
The ®nal presentation in this session, although not related to the autocrine, paracrine or endocrine function of adipose tissue, was certainly very innovative and unusual. Yuan-Di Halvorsen showed how adipose tissue-derived stromal cells, obtained from human subcutaneous adipose tissue samples, can be developed in primary culture in amounts suf®cient to meet commercial demands for adipocytes or pre-adipocytes. These human adipocytes and pre-adipocytes are obviously very useful for academic research, but are being used mainly for high-throughput screening by pharmaceutical and biotechnology companies. The development and production of these cells formed only a small part of Halvorsen's presentation, because she then went on to describe how the same stromal cells could be made to differentiate into cells resembling osteoblasts that, given the appropriate conditions, will mineralize their extracellular matrix. This raises the intriguing possibility that samples of human adipose tissue could be used to develop suf®cient, differentiated osteoblasts to treat various orthopaedic, rheumatological and periodontal disorders. Furthermore, given suf®cient notice, samples of adipose tissue could be taken and developed such that the patient receives autologous differentiated osteoblasts, thereby avoiding the hazards of rejection and unknown or undetected infection. Of course, one need not stop here, and there is no reason at all why these human stromal cells should not be engineered to express and secrete various therapeutic agents. However, we are now in danger of entering the realms of science ®ction, and this seems a good time to stop and let the reader form their own opinion on where these latest advances in adipose tissue biology are leading.
